The Manufacturers Life Insurance Company Sells 816 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

The Manufacturers Life Insurance Company lessened its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 5.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,151 shares of the specialty pharmaceutical company’s stock after selling 816 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Collegium Pharmaceutical were worth $585,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. nVerses Capital LLC grew its position in shares of Collegium Pharmaceutical by 1,600.0% during the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,600 shares during the period. GAMMA Investing LLC boosted its stake in Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after acquiring an additional 792 shares during the last quarter. CWM LLC grew its holdings in Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 736 shares during the period. AXA S.A. acquired a new position in Collegium Pharmaceutical during the second quarter valued at approximately $209,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Collegium Pharmaceutical by 61.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,196 shares of the specialty pharmaceutical company’s stock valued at $239,000 after purchasing an additional 2,352 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. HC Wainwright lifted their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, Piper Sandler restated a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $42.60.

Collegium Pharmaceutical Price Performance

Shares of COLL stock opened at $30.09 on Friday. Collegium Pharmaceutical, Inc. has a 12-month low of $28.75 and a 12-month high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The firm has a fifty day moving average of $33.24 and a 200-day moving average of $34.37. The company has a market capitalization of $970.40 million, a price-to-earnings ratio of 12.97 and a beta of 0.80.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.